Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

He was 12 years into his virology research career at Gilead and the first daily single tablet regimen for HIV treatment was still awaiting approval. Treatment options for people living with HIV at ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...